MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

BioMarin Pharmaceutical Inc

Open

BrancheGesundheitswesen

62.65 -0.05

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

61.49

Max

62.77

Schlüsselkennzahlen

By Trading Economics

Einkommen

19M

125M

Verkäufe

1.6M

747M

KGV

Branchendurchschnitt

26.539

57.333

EPS

0.92

Gewinnspanne

16.719

Angestellte

3,040

EBITDA

39M

195M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+57.54% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

1. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-729M

11B

Vorheriger Eröffnungskurs

62.7

Vorheriger Schlusskurs

62.65

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

BioMarin Pharmaceutical Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Juni 2024, 17:41 UTC

Wichtige Markttreiber

Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion

21. Aug. 2024, 11:30 UTC

Top News

S&P 500 Futures Up In Premarket Trading; Target, Keysight Technologies Lead

Peer-Vergleich

Kursveränderung

BioMarin Pharmaceutical Inc Prognose

Kursziel

By TipRanks

57.54% Vorteil

12-Monats-Prognose

Durchschnitt 97.58 USD  57.54%

Hoch 126 USD

Tief 70 USD

Basierend auf 21 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für BioMarin Pharmaceutical Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

21 ratings

16

Buy

5

Halten

0

Sell

Technischer Score

By Trading Central

61.5 / 63.39Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.